1
|
Matthews JC, Dardas TF, Dorsch MP, Aaronson KD. Right-sided heart failure: Diagnosis and treatment strategies. CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE 2008; 10:329-41. [DOI: 10.1007/s11936-008-0053-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
2
|
Gilchrist NA. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension. J Pharm Technol 2008. [DOI: 10.1177/875512250802400304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of ambrisentan, a selective endothelin type A (ETA) receptor antagonist, for the treatment of pulmonary arterial hypertension (PAH). Data Sources: Articles were identified through a search of the MEDLINE (1950–November 2007) database for English-language articles containing the key words ambrisentan, pulmonary arterial hypertension, pulmonary hypertension, endothelin antagonist, and endothelin type A receptor. References from publications identified in this search were reviewed for relevant information. Unpublished data received from the manufacturer were also included in this review. Study Selection and Data Extraction: All articles identified from the data search were reviewed for relevant information. Applicable information was included in this review. Data Synthesis: Ambrisentan is the first oral nonsulfonamide ETA receptor antagonist approved by the FDA for use in patients with PAH who have World Health Organization class II or III symptoms. To date, the use of ambrisentan in the treatment of PAH has been evaluated by only 1 published Phase 2 clinical trial and 3 unpublished Phase 3 clinical trials. Ambrisentan therapy during clinical trials resulted in a significant improvement in exercise capacity and hemodynamic parameters. Metabolism occurs by hepatic glucuronidation, with elimination primarily through nonrenal pathways. A half-life of 15 hours allows for once-daily dosing. The most common adverse effect reported during clinical trials was peripheral edema. Hepatotoxicity occurred very infrequently, with affected patients requiring only a dose reduction to resolve an episode of elevated aminotransferases. Conclusions: Ambrisentan appears to be a promising treatment option for patients affected by PAH, given its improved drug–drug interaction and hepatotoxicity profile compared with other endothelin antagonists. Future studies are needed to determine the role of ambrisentan in the treatment of PAH and the selection of optimal endothelin antagonism.
Collapse
Affiliation(s)
- Neil A Gilchrist
- NEIL A GILCHRIST PharmD BCPS, Clinical Pharmacy Specialist, Critical Care, Department of Pharmacy, UMass Memorial Medical Center, Worcester, MA; Adjunct Faculty, Massachusetts College of Pharmacy and Health Sciences, Worcester
| |
Collapse
|
3
|
Sterling J. Recent Publications on Medications and Pharmacy. Hosp Pharm 2007. [DOI: 10.1310/hpj4205-481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Hospital Pharmacy presents this feature to keep pharmacists abreast of new publications in the medical/pharmacy literature. Articles of interest will be abstracted monthly regarding a broad scope of topics. Suggestions or comments may be addressed to: Jacyntha Sterling, Drug Information Specialist at Saint Francis Hospital, 6161 S Yale Ave., Tulsa, OK 74136 or e-mail: jasterling@saintfrancis.com .
Collapse
|
4
|
Hegde S, Schmidt M. Chapter 32 To Market, To Market – 2006. ANNUAL REPORTS IN MEDICINAL CHEMISTRY VOLUME 42 2007. [DOI: 10.1016/s0065-7743(07)42032-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
|